Dual inhibition of MEK1/2 and MEK5 suppresses the EMT/migration axis in triple-negative breast cancer through FRA-1 regulation.

Saved in:
Bibliographic Details
Title: Dual inhibition of MEK1/2 and MEK5 suppresses the EMT/migration axis in triple-negative breast cancer through FRA-1 regulation.
Authors: Hoang VT; Department of Medicine, Section of Hematology and Oncology, Tulane University School of Medicine, New Orleans, Louisiana, USA., Matossian MD; Department of Medicine, Section of Hematology and Oncology, Tulane University School of Medicine, New Orleans, Louisiana, USA., La J; Department of Medicine, Section of Hematology and Oncology, Tulane University School of Medicine, New Orleans, Louisiana, USA., Hoang K; Department of Medicine, Section of Hematology and Oncology, Tulane University School of Medicine, New Orleans, Louisiana, USA., Ucar DA; Department of Genetics and Stanley S. Scott Cancer Center, LSUHSC, New Orleans, Louisiana, USA., Elliott S; Department of Medicine, Section of Hematology and Oncology, Tulane University School of Medicine, New Orleans, Louisiana, USA., Burks HE; Department of Medicine, Section of Hematology and Oncology, Tulane University School of Medicine, New Orleans, Louisiana, USA., Wright TD; Department of Pharmacology, Duquesne University, School of Pharmacy, Pittsburgh, Pennsylvania, USA., Patel S; Department of Pharmacology, Duquesne University, School of Pharmacy, Pittsburgh, Pennsylvania, USA., Bhatt A; Department of Pharmacology, Duquesne University, School of Pharmacy, Pittsburgh, Pennsylvania, USA., Phamduy T; Department of Physics, Tulane University, New Orleans, Louisiana, USA., Chrisey D; Department of Physics, Tulane University, New Orleans, Louisiana, USA., Buechlein A; Medical Sciences Program, Indiana University School of Medicine-Bloomington, Bloomington, Indiana, USA., Rusch DB; Center for Genomics and Bioinformatics, Indiana University, Bloomington, Indiana, USA., Nephew KP; Medical Sciences Program, Indiana University School of Medicine-Bloomington, Bloomington, Indiana, USA., Anbalagan M; Department of Structural and Cellular Biology, Tulane University School of Medicine, New Orleans, Louisiana, USA., Rowan B; Department of Structural and Cellular Biology, Tulane University School of Medicine, New Orleans, Louisiana, USA., Cavanaugh JE; Department of Pharmacology, Duquesne University, School of Pharmacy, Pittsburgh, Pennsylvania, USA., Flaherty PT; Department of Medicinal Chemistry, Duquesne University, School of Pharmacy, Pittsburgh, Pennsylvania, USA., Miele L; Department of Genetics and Stanley S. Scott Cancer Center, LSUHSC, New Orleans, Louisiana, USA., Collins-Burow BM; Department of Medicine, Section of Hematology and Oncology, Tulane University School of Medicine, New Orleans, Louisiana, USA.; Tulane Cancer Center, New Orleans, Louisiana, USA., Burow ME; Department of Medicine, Section of Hematology and Oncology, Tulane University School of Medicine, New Orleans, Louisiana, USA.
Source: Journal of cellular biochemistry [J Cell Biochem] 2021 Aug; Vol. 122 (8), pp. 835-850. Date of Electronic Publication: 2021 Apr 20.
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 8205768 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-4644 (Electronic) Linking ISSN: 07302312 NLM ISO Abbreviation: J Cell Biochem Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1097-4644
DOI:10.1002/jcb.29916